Sagimet Biosciences has secured a global, exclusive license from Teva’s TAPI Technology & API Services to use innovative forms of resmetirom API in a planned fixed-dose combination with denifanstat, its once-daily FASN inhibitor, for metabolic dysfunction-associated steatohepatitis (MASH). The company is already running a Phase 1 pharmacokinetic study of the denifanstat–resmetirom combination to assess multiple- and single-dose PK, potential drug–drug interactions, and safety, with topline data expected by year-end 2025. Pending those results and regulatory consultation, Sagimet aims to move the combination into Phase 2 for F4 cirrhotic MASH in the second half of 2026 and to advance a once-daily FDC—potentially not requiring weight-based dosing—into Phase 3.
The strategic thrust is clear: in the post-approval era of resmetirom for non-cirrhotic MASH, the competitive frontier is shifting toward combination therapy and formulation advantage, particularly for F4 patients, for whom no drug is approved. By anchoring a THR-β agonist to a lipogenesis and fibrosis-targeting FASN inhibitor, Sagimet is betting on mechanistic complementarity to drive fibrosis regression and clinical outcomes in a population at the highest risk for decompensation and transplant. The tie-up with TAPI adds a nuanced edge—control of novel API forms that could enable manufacturability, simplify dosing, and position intellectual property for an FDC, a playbook long used in cardiometabolic and antiviral markets but still emerging in MASH.
This matters now because payers, hepatologists, and patients are demanding more than histologic signals; they want durable improvement in fibrosis and fewer liver-related events, especially in F4. For HCPs, a single-tablet regimen could reduce complexity compared with current weight-based dosing schemes, thereby improving adherence in patients with chronic disease and polypharmacy. For payers, the bar will be comparative value against resmetirom monotherapy and other late-stage assets, with evidence expectations extending beyond biopsy surrogates to event-based endpoints. For competitors, the move underscores the risk that monotherapies become stepping stones to combination standards, raising the stakes for lifecycle management and partnerships around THR-β backbones.
The deal also reflects broader industry dynamics. Biotechs with differentiated mechanisms are converging on combination regimens to address MASH’s multifactorial biology, with THR-β agonists, FGF21 analogs, and metabolic/anti-fibrotic agents forming the core mix. At the same time, API and CDMO providers are asserting greater influence through patents on crystalline forms and manufacturability know-how that can unlock FDC feasibility and confer tactical IP advantages. This hybrid of development biology and a chemistry-of-matter strategy could serve as a template for MASH, where formulation can be as determinative as mechanism in establishing commercial defensibility and payer-friendly dosing.
Execution risk will hinge on three near-term questions. First, can the Phase 1 data de-risk drug–drug interactions and support a non-weight-based dose that simplifies real-world use without compromising exposure? Second, will regulators accept an FDC development path for F4 that leans on established component safety while demanding hard clinical outcomes, potentially lengthening timelines but strengthening payer narratives? Third, how will originator dynamics around resmetirom shape freedom to operate and future market access, as innovators and partners converge on THR-β–anchored combinations? The following 12 months of PK readouts and formulation selection will signal whether Sagimet’s chemistry-enabled combination strategy can set the pace toward an FDC-led standard in cirrhotic MASH.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
